Abstract
Purpose
To determine the pharmacokinetics of adaptively dosed carboplatin when administered in combination with the bradykinin agonist, lobradimil (RMP-7, Cereport), to pediatric patients with brain tumors.
Methods
Carboplatin pharmacokinetic studies were performed on 21 of 25 children with primary brain tumors who received carboplatin and lobradimil on two consecutive days every 28 days in a phase I dose-escalation trial of lobradimil. Carboplatin was adaptively dosed, based on the radioisotopic glomerular filtration rate (GFR) to achieve a target plasma area under the concentration vs time curve (AUC) of 3.5 mg⋅min/ml per dose ×2 (2.5 mg⋅min/ml per dose ×2 in patients with prior craniospinal radiation or myeloablative chemotherapy). The adaptive dosing formula was: carboplatin dose (mg/m2)=target AUC (mg⋅min/ml) × [0.93 × GFR (ml/min/m2)+15]. Carboplatin was infused over 60 min (n=15) or 15 min (n=6). The 10-min lobradimil infusion (100–600 ng/kg ideal body weight) began 5 min before the end of the carboplatin infusion. Frequent blood samples were drawn over 24 h after the first dose of carboplatin/lobradimil. Ultrafilterable platinum was measured by atomic absorption spectroscopy, and the AUC of ultrafilterable platinum was derived using the linear trapezoidal rule and extrapolated to infinity.
Results
The median GFR was 65 ml/min/m2 (range 38–95 ml/min/m2) and the median carboplatin doses for the 2.5 and 3.5 mg min/ml target AUCs were 154 and 276 mg/m2/day (124–235 and 179–360 mg/m2/day), respectively. The measured carboplatin AUC exceeded the target AUC in all 21 patients by a median of 35% (range 0.2–131%). The median carboplatin AUCs at the 2.5 and 3.5 mg⋅min/ml target AUCs were 3.4 and 4.8 mg⋅min/ml (2.51–5.8 and 3.9–7.7 mg⋅min/ml), respectively. Carboplatin clearance was lower than values previously reported in children and correlated poorly with GFR (r 2=0.14).
Conclusions
Adaptive dosing of carboplatin based on GFR overestimated the dose required to achieve the target carboplatin AUC in pediatric patients with brain tumors treated with concurrent lobradimil. The degree to which the measured carboplatin AUC exceeded the target AUC appeared to be greater at higher doses of lobradimil, suggesting that the failure of the adaptive dosing method was related to an unexpected pharmacokinetic drug interaction.
Similar content being viewed by others
References
Elliott PJ, Hayward NJ, Huff MR, et al (1996) Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol 141:214–224
Raymond JJ, Robertson DM, Dinsdale HB (1986) Pharmacological modification of bradykinin induced breakdown of the blood-brain barrier. Can J Physiol Pharmacol 13:214–220
Liu Y, Hashizume L, Chen Z, et al (2001) Correlation between bradykinin-induced blood-tumor barrier permeability and B2 receptor expression in experimental brain tumors. Neurol Res 23:379
Inamura T, Black KL (1994) Bradykinin selectively opens blood-tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab 14:862–870
Matsukado K, Inamura T, Nakano S, et al (1996) Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 39:125–133
Elliott PJ, Hayward NJ, Dean RL, et al (1996) Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors. Cancer Res 56:3998–4005
Inamura T, Nomura T, Bartus RT, et al (1994) Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg 81:752–758
Warren KE, Patel MC, Aikin AA, et al (2001) Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors. Cancer Chemother Pharmacol 48:275–282
Harland S, Newell D, Siddik Z, et al (1984) Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) in patients with normal and impaired renal function. Cancer Res 44:1693–1697
Egorin M, van Echo D, Tipping S, et al (1984) Pharmacokinetics and dosage reduction of cis-diammine (1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 44:5432–5438
Calvert A, Newell D, Gumbrell L, et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748–1756
Newell D, Pearson A, Balmanno K, et al (1993) Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J Clin Oncol 11:2314–2323
Marina N, Rodman J, Shema S, et al (1993) Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors. J Clin Oncol 11:554–560
Marina N, Rodman JH, Murry DJ, et al (1994) Phase 1 study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. J Natl Cancer Inst 86:554
Thomas HD, Lind MJ, Ford J, et al (2000) Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist cereport (RMP-7) for the treatment of brain tumors. Cancer Chemother Pharmacol 45:284–290
Spierto FW, MacNeil ML, Burtis CA (1979) The effect of temperature and wavelength on the measurement of creatinine with the Jaffe procedure. Clin Biochem 12:18
Russell C, Bischoff P, Kantzen F, et al (1985) Measurement of glomerular filtration rate: single injection plasma clearance method without urine collection. J Nucl Med 26:1243–1247
DuBois D, Dubois E (1916) Formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17:863
Ghazal-Aswad S, Calvert AH, Newell DR 1996) A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol 37:429–434
Thomas H, Boddy A, English M, et al (2000) Prospective validation of renal function-based carboplatin dosing in children with cancer: a United Kingdom Children’s Cancer Study Group trial. J Clin Oncol 18:3614–3621
Riccardi R, Riccardi A, Lasorella A, et al (1994) Clinical pharmacokinetics of carboplatin in children. Cancer Chemother Pharmacol 33:477–483
Matsumura Y, Tadano K, Yamasaki T (1999) Renal haemodynamic and excretory responses to bradykinin in anesthetized dogs. Clin Exp Pharmacol Physiol 26:645
Granger JP, Hall JE (1985) Acute and chronic actions of bradykinin on renal function and arterial pressure. Am J Physiol 248 (1 Pt 2):F87
Lortie M, Regoli D, Rhaleb NE, et al (1992) The role of B1- and B2-kinin receptors in the renal tubular and hemodynamic response to bradykinin. Am J Physiol 262 (1 Pt 2):R72
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Warren, K., Gervais, A., Aikin, A. et al. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors. Cancer Chemother Pharmacol 54, 206–212 (2004). https://doi.org/10.1007/s00280-004-0791-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-004-0791-4